Skip to main content

Table 1 Antibiotic resistance in patients with resistant E. cloacae and susceptible E. cloacae

From: Dynamics of colistin and tobramycin resistance among Enterobacter cloacae during prolonged use of selective decontamination of the digestive tract

Antibiotic (combination) Susceptible E. cloacae (n = 2075 unique patients, 3030 isolates) Multi-resistant E. cloacae (n = 373 patients, 1373 isolates) Selected for WGS (n = 112 isolates)
Patients (n) tested % non-susceptible / positivea Patients (n) tested % non- susceptible / positivea % non- susceptible / positivea
ciprofloxacin 2075 1.3 373 42.9 28.6
colistin 1122 0 205 68.8 78.4b
gentamicin 2075 0.2 373 82.8 86.6
imipenem 2070 0.2 373 5.6 6.3
meropenem 2073 0.1 373 4.8 6.3
tobramycin 2075 0 373 89.3 87.5
trimethoprim/ sulfamethoxazole 2075 5.5 373 34.6 86.6
ESBL production 873 0 156 71.2 72.3
CIP or SXT 2075 0.6 373 17.7 5.4
CIP or SXT or MEM 2064 0 349 0.9 0
CIP or SXT or MEM or CST 1118 0 187 0.5 0
  1. CIP ciprofloxacin, CST colistin, ESBL extended-spectrum beta-lactamase, MEM meropenem, n number, SXT trimethoprim/ sulfamethoxazole, WGS whole-genome sequencing
  2. a% non-susceptible for antibiotics or % ESBL positive
  3. b111/112 isolates tested
  4. Number of resistant E. cloacae isolates tested: ciprofloxacin: n = 1373, colistin: n = 784, gentamicin: n = 1373, imipenem: n = 1373, meropenem: n = 1371, tobramycin: n = 1373, trimethoprim/ sulfamethoxazole: n = 1372. Number of susceptible E. cloacae isolates tested: ciprofloxacin: n = 3030, colistin: n = 1613, gentamicin: n = 3030, imipenem: n = 3024, meropenem: n = 3028, tobramycin: n = 3030, trimethoprim/ sulfamethoxazole: n = 3030